Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103880 | 0.86 | SMPD1 (0.69) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL4109073 | 0.83 | KDM4E (0.64) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL4108962 | 0.80 | MEN1 (0.67) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL7435099 | 0.79 | ATM (0.76) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL28694522 | 0.78 | SMPD1 (0.69) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL4025101 | 0.78 | KMT2A (0.65) | SMN1; SMN2ALDH1A1KMT2AMEN1ATM | |
| Hydrochloric Acid SCHEMBL11808765 | 0.77 | ATM (0.73) | SMN1; SMN2ALDH1A1KDM4EGLAKMT2A | |
| Hydrochloric Acid SCHEMBL28691173 | 0.77 | SMPD1 (0.67) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL4103633 | 0.77 | SMPD1 (0.70) | SMN1; SMN2SMPD1ALDH1A1KDM4EGLA | |
| SCHEMBL1581543 | 0.77 | ATM (0.68) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938525-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to cell types | NLIFE THERAPEUTICS, S.L. (ES) | 2018-04-10 | — | — | US | disclosed |
| US-20150315575-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | PALOMO LIMITED (CY) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315575-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES | MSR1, HAVCR2, SNRPE | SMN1; SMN2 262/4885SMPD1 1732/4885ALDH1A1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.